Akari Therapeutics
AKTX
6 hedge funds and large institutions have $12.9M invested in Akari Therapeutics in 2014 Q1 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$4.75M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$4.75M |
| 3 |
BC
Broadfin Capital
New York
|
+$3.34M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$735K |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$283K |
Top Sellers
AKTX Hedge Fund Activity: Q1 2014 in Review
6 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q1 2014, worth a combined $12.9M.
Buyers outnumbered sellers: 6 funds opened new AKTX positions and 0 closed out — a net gain of 6 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $4.75M.
- 6 institutional investors held Akari Therapeutics (AKTX) as of Q1 2014, up from 0 in Q4 2013.
- Funds reported $12.9M of Akari Therapeutics stock for Q1 2014.
- 6 funds opened new Akari Therapeutics positions in Q1 2014 and 0 closed out, a net change of +6 holders.
- The largest Akari Therapeutics buyer in Q1 2014 was Baker Bros. Advisors, an estimated $4.75M added.
Based on aggregated 13F filings for Q1 2014.